https://malotilateinhibitor.co....m/initial-statement-
Although ALK-positive ALCL patients respond notably to ALK inhibitors, the introduction of weight is inevitable, which needs the development of new healing techniques for ALK-positive ALCL. Right here, we investigated the anticancer tasks of N-(2((5-chloro-2-((2-methoxy-6-(4-methylpiperazin-1-yl)pyridin-3yl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (ZX-29), a newly synthesized ALK inhibitor, against nucleophosmin-ALK-positive cell line K
Like
Comment
Share
